Lab
Pathway Diagnostics LLC
Pathway Diagnostics LLC was paid $548K by Medicaid between Jan 2018 and Aug 2019, across 80 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 23% of everything it billed.
33Billing provider infoPATHWAY DIAGNOSTICS LLC
PICAYUNE, MS 39466
PICAYUNE, MS 39466
33aNPI1710347703assigned 03/03/2016
33bProvider typeClinical Medical Laboratory
28Total paid$548K
24GClaims29,659
24DCodes billed80
24AFirst – last monthJan 2018 – Aug 2019
Compared with peers
Next to other Clinical Medical Laboratory providers in Mississippi
Rank by total paid#13 of 35
Median peer was paid$136K
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,754 | $346K | |
| 2019 | 6,905 | $202K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 23% | 921 | 511 | $124K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 14% | 1,161 | 679 | $75K |
| 87506 | 6.4% | 175 | 160 | $35K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.0% | 1,536 | 1,275 | $33K |
| 87541 | 2.7% | 762 | 664 | $15K | |
| 87556 | 2.4% | 680 | 575 | $13K | |
| 87581 | 2.4% | 666 | 575 | $13K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.4% | 664 | 573 | $13K |
| 87486 | 2.4% | 665 | 574 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.3% | 340 | 254 | $13K |
| 87500 | 2.2% | 600 | 498 | $12K | |
| 87641 | 2.1% | 594 | 497 | $12K |
68 more codes
| 87483 | 1.4% | 152 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 539 | $7K |
| 80373 | 1.3% | 609 | $7K | |
| 87653 | 1.2% | 254 | $7K | |
| 80368 | 1.2% | 563 | $7K | |
| 80372 | 1.2% | 536 | $6K | |
| 87498 | 1.2% | 214 | $6K | |
| 87496 | 1.1% | 214 | $6K | |
| 87561 | 1.1% | 194 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 638 | $6K |
| 80357 | 1.1% | 511 | $6K | |
| 87481 | 1.0% | 269 | $6K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.0% | 503 | $6K |
| 80323 | <1% | 565 | $5K | |
| 80367 | <1% | 432 | $5K | |
| 80336 | <1% | 399 | $5K | |
| 87640 | <1% | 810 | $5K | |
| 87632 | <1% | 100 | $4K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 500 | $4K |
| 80356 | <1% | 786 | $4K | |
| 87503 | <1% | 367 | $4K | |
| 80346 | <1% | 598 | $3K | |
| 80338 | <1% | 444 | $3K | |
| 80361 | <1% | 607 | $3K | |
| 80348 | <1% | 563 | $3K | |
| 80354 | <1% | 532 | $3K | |
| 80349 | <1% | 564 | $3K | |
| 80358 | <1% | 567 | $3K | |
| 80365 | <1% | 555 | $3K | |
| 83992 | <1% | 726 | $3K | |
| 80350 | <1% | 762 | $3K | |
| 80324 | <1% | 596 | $2K | |
| 80363 | <1% | 486 | $2K | |
| 80359 | <1% | 504 | $2K | |
| 80345 | <1% | 578 | $2K | |
| 80335 | <1% | 124 | $2K | |
| 80353 | <1% | 449 | $2K | |
| 80321 | <1% | 179 | $2K | |
| 80342 | <1% | 102 | $2K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 171 | $1K |
| 80371 | <1% | 305 | $1K | |
| 80360 | <1% | 132 | $1K | |
| 80352 | <1% | 128 | $990.00 | |
| 80370 | <1% | 59 | $982.24 | |
| 80333 | <1% | 44 | $693.00 | |
| 80332 | <1% | 48 | $693.00 | |
| 80362 | <1% | 58 | $650.19 | |
| 80325 | <1% | 52 | $619.20 | |
| 80369 | <1% | 69 | $564.94 | |
| 80355 | <1% | 39 | $448.02 | |
| 82570 | <1% | 613 | $424.73 | |
| 86768 | <1% | 42 | $350.19 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15 | $265.14 |
| 82670 | <1% | 12 | $249.32 | |
| 83986 | <1% | 622 | $246.95 | |
| 87634 | <1% | 141 | $230.07 | |
| 84403 | <1% | 12 | $205.60 | |
| 83921 | <1% | 14 | $162.09 | |
| 82542 | <1% | 16 | $158.08 | |
| 84146 | <1% | 12 | $154.24 | |
| 82607 | <1% | 16 | $149.90 | |
| 83001 | <1% | 12 | $148.00 | |
| 82746 | <1% | 16 | $146.30 | |
| 83003 | <1% | 12 | $132.72 | |
| 82533 | <1% | 12 | $129.84 | |
| 87529 | <1% | 23 | $111.15 | |
| 87501 | 0% | 97 | $0.00 | |
| 80366 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUSTAFA, SAMIYA (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Performance Laboratories LLC | Oklahoma City, OK | $386K |
| Lazarus Services, LLC | New Orleans, LA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.